Paul Collins is currently a Senior Director in Small Molecule Design and Development at Eli Lilly and Company in Indianapolis. In his current role, Paul has responsibility for product and process development activities for Lilly’s pre-FHD synthetic molecule development portfolio. Prior to this role, he oversaw ongoing efforts for technology platform development, including continuous manufacturing, of both API and drug product.
Paul has also been a Director in Bioprocess Development, Chemical Technology Development, and Chemical Process Development. During his time at Lilly, Paul has been instrumental in recruiting and developing both new and experienced engineers, as well as starting new technical capabilities necessary for Lilly’s current efforts in continuous manufacturing and modeling. Paul started his career with Merck and Company, working in both manufacturing and R&D. Across both companies, Paul has been involved in the process development, registration, and commercialization of six marketed pharmaceuticals.
Outside of Lilly, Paul has been heavily involved with AIChE’s Pharmaceutical Division over the past decade, shaping future programming directions as well as chairing the pharmaceutical forum in 2015 and 2016. He also is part of ISPE’s PQLI programming team looking at future technical-regulatory interaction topics for advanced manufacturing platforms.
Paul received his BE in Chemical Engineering from Vanderbilt University in 1988 and his PhD in Biochemical Engineering from Northwestern in 1997.